secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2022-05-17T23:59:59+00:00
Accession:  0001564590-22-020476
Event type: other_material
Sentiment:  positive
Materiality: 0.65
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma launches Phase 3 EFZO-FIT trial of efzofitimod in pulmonary sarcoidosis, citing positive Phase 1b/2a data
--------------------------------------------------------------------------------

- Phase 3 EFZO-FIT will enroll 264 patients; primary endpoint is steroid reduction; secondary endpoints include lung function and symptoms.
- Phase 1b/2a data showed dose-dependent improvements; 5.0 mg/kg group had three patients completely taper off steroids.
- Efzofitimod demonstrated control of inflammatory biomarkers (IFN-γ, IL-6, IP-10, MCP-1, TNFa) over 24 weeks.
- Two higher doses (3.0 and 5.0 mg/kg) improved lung function measures (FVC, DLCO) vs placebo.
- Trial expected to initiate Q3 2022; Phase 1b/2a results presented at ATS 2022 conference May 17.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022020476/0001564590-22-020476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459022020476/life-8k_20220516.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-020476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer